Orsini, a leader in rare disease pharmacy solutions, announced today that it is the exclusive specialty pharmacy partner for ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved ...

Since 2008, the FDA has approved 11 treatments for a rare genetic condition called hereditary angioedema (HAE), three of ...

Dawnzera, a prekallikrein-directed antisense oligonucleotide, is supplied as a 80mg/0.8mL solution in a single-dose autoinjector.

Dawnzera is the first and only RNA-targeted prophylactic therapy to be approved for hereditary angioedema in adults and ...

Dawnzera is the third medicine cleared by U.S. regulators this year for the rare genetic condition, and the second wholly owned medicine Ionis has brought to market.

Developed by Ionis Pharmaceuticals, Dawnzera is the first RNA-targeted medicine approved for HAE, designed to target plasma ...

Ionis on Thursday said the FDA green light covers Dawnzera for prophylaxis to prevent attacks of hereditary angioedema in patients 12 years of age and older and makes the drug is the first and only ...

By Sneha S K and Bageshri Banerjee (Reuters) -The U.S. Food and Drug Administration on Thursday approved Ionis ...

Dawnzera (donidalorsen) is a new medicine approved to help prevent attacks of a rare genetic swelling disorder known as hereditary angioedema (HAE) in people aged 12 or older. Affecting about ...

Dawnzera is the first and so far only RNA-targeting therapy approved as a prophylactic treatment for hereditary angioedema ...

Wall Street analysts boosted their targets on Ionis Pharmaceuticals after the FDA approved its RNA-based drug Dawnzera for hereditary angioedema, sparking a surge in retail chatter. BofA Securities ...